医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Medtech Startup CoreTissue BioEngineering to Be the First Japanese Startup at JPOD @ Boston

2022年03月16日 PM12:19
このエントリーをはてなブックマークに追加


 

YOKOHAMA, Japan

CoreTissue BioEngineering Inc., a medical device company developing an artificial ligament derived from decellularized animal tissue, was accepted into Johnson & Johnson Innovation – JPOD @ Boston.

CoreTissue BioEngineering will expand its footprint and accelerate business development in the US through its support team and select key opinion leaders (KOLs).

About CoreTissue BioEngineering Inc.

Based in Yokohama, Japan, CoreTissue BioEngineering, Inc. is a spinout company from Waseda University in Japan. We feel our team of Harvard-trained biomedical scientist, seasoned senior management in medical device development, and experienced clinical research professional has the right talents to carry this mission to potential success.

Following our success in developing artificial ligament for ACL reconstruction surgery, we plan to further apply our technology platform to the development of medical devices for the broader human musculoskeletal system.

CoreTissue BioEngineering has already validated a proof-of-concept of the product in an ovine large animal study with a prototype developed using these technologies. The company has received strong backing from the Japanese government, the Japan Agency for Medical Research and Development (AMED) for development from early feasibility through pivotal trial.

For more information, visit https://www.coretissue.com/?lang=en

View source version on businesswire.com: https://www.businesswire.com/news/home/20220302006183/en/

CONTACT

Chiaki Waki

CoreTissue BioEngineering Inc.

Email: chiaki.waki@coretissue.com

Tel: +81-80-7638-1286

TimeLine:

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024